In a study published in Nature Geoscience, a research team led by Prof. Liu Lingli from the Institute of Botany of the Chinese Academy of Sciences (IBCAS) has identified a mean annual precipitation ...

While NASA imagery has shown evidence of ancient rivers and lakes on Mars that transitioned to dry dunes, uncertainty remains ...

Knowledge is power, so here’s how to find power-gobbling data centers near you. Knowledge is power, so here’s how to find power-gobbling data centers near you. is a policy reporter at The Verge ...

Florida-based AP governance firm selected as an RFP-stage contender, reinforcing its leadership in SAP vendor and customer master data compliance, modernization, and enterprise AP controls. PORT ST.

ROBSTOWN, Texas — A massive new artificial intelligence data center is headed to Nueces County, bringing billions in investment and hundreds of jobs to the region. Energy and digital infrastructure ...

Erasca Inc. (NASDAQ:ERAS) is one of the best performing NASDAQ stocks according to Wall Street analysts. On April 27, Erasca announced positive preliminary Phase 1 data for ERAS-0015, a pan-RAS ...

Developers of the proposed data center along W.Va. 62 north of Point Pleasant, West Virginia, have submitted their application for a construction permit to the West Virginia Department of ...

Erasca has backed up bullish claims about its pan-RAS drug having a best-in-class profile, publishing phase 1 data that an analyst said reveal a “home run profile.” But with a patient dying and ...

Greetings, and welcome to the Erasca Corporate Update Call. [Operator Instructions] As a reminder, this conference is being recorded. It is now my pleasure to introduce Jonathan Lim, CEO and Chairman.

Robust monotherapy efficacy in KRAS G12X NSCLC: 62% uORR in 2L+ and 75% uORR in post-ICI/platinum 2/3L at 16-32 mg QD PAD, and 64% uORR in 2L+ at 24-32 mg QD RDE Robust monotherapy efficacy in 2L KRAS ...

SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Erasca, Inc. (Nasdaq: ERAS), a clinical-stage precision oncology company singularly focused on discovering, developing, and commercializing therapies for ...

After dropping headline-grabbing phase 3 data for its pancreatic cancer candidate daraxonrasib last week, Revolution Medicines is not resting on its laurels. The Bay Area biotech has spent several ...